Showing results 1 to 1 of 1
| Issue Date | Title | Journal Title |
|---|---|---|
| 2026 | Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma | ESMO OPEN |